ArQule starts Phase 2 trials
October 31, 2007 09:03 AM
E-mail|
|Comments
()|
Text size
–
+
Woburn biotechnology firm ArQule Inc. announced today the initiation of two Phase 2 trials for ARQ 197, an inhibitor of the c-Met molecule.
The trials will be conducted in patients with Microphthalmia Transcription Factor, or MiT, tumors and in patients with pancreatic cancer, the company said.
(By Chris Reidy, Globe staff)
Comment
Permalink
E-mail
